- /
- Supported exchanges
- / US
- / CELC.NASDAQ
Celcuity LLC (CELC NASDAQ) stock market data APIs
Celcuity LLC Financial Data Overview
Celcuity Inc., a clinical-stage biotechnology company, focuses on the development of targeted therapies for the treatment of various solid tumors in the United States. The company's lead drug candidate includes Gedatolisib, which selectively targets various Class I isoforms of phosphatidylinositol-3-kinase (PI3K) and the two mechanistic targets of rapamycin (mTOR) sub-complexes, mTORC1 and mTORC2 to treat patients with hormone receptor positive (HR+), human epidermal growth factor receptor 2 negative (HER2-) or HR+/HER2-, advanced or metastatic breast cancer (ABC), and patients with metastatic castration resistant prostate cancer (mCRPC). It also engages in developing of CELsignia diagnostic platform. The company had a license agreement with Pfizer Inc. for the development and commercialization rights to Gedatolisib. Celcuity Inc. was founded in 2011 and is based in Minneapolis, Minnesota.
* We provide hundreds of fields of fundamental data, including EBITDA, P/E ratio, PEG ratio, trailing P/E, shareholders, insider transactions, technical metrics, dividends, splits, earnings, and more. Check out our Fundamental Data API.
ETFs with Celcuity LLC (top by weight)
* We provide detailed information about ETF constituents through our Fundamentals API for ETFs. Read the documentation to learn more.
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Or get access to advanced financial data starting only $19.99
Get Celcuity LLC data using free add-ons & libraries
Get Celcuity LLC Fundamental Data
Celcuity LLC Fundamental data includes:
- Net Revenue:
- EBITDA: -159 268 000
- Earnings Per Share:
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
End-of-day & Earnings data
What’s included:
- Latest Release: 2026-03-19
- EPS/Forecast: -1.05
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Celcuity LLC News
New
Does This $25 Million Bet on a Stock Down 61% Signal Turnaround Potential at $6?
Sio Capital Management disclosed a new position in Organon(NYSE:OGN) on February 17, 2026, acquiring 3,421,765 shares worth $24.53 million at quarter’s end. What happened According to a filing wit...
Inside One Fund's $170 Million Bet on a Biotech Stock Up 1,040% in a Year Amid FDA Review for Breast Cancer Drug
Deerfield Management Company disclosed a substantial purchase of Celcuity(NASDAQ:CELC) in its February 17, 2026, SEC filing, adding 980,470 shares in the fourth quarter. The estimated value of the tra...
Inside One Fund's $170 Million Bet on a Biotech Stock Up 1,040% in a Year Amid FDA Review for Breast Cancer Drug
Key Points Deerfield Management Company increased its Celcuity stake by 980,470 shares in the fourth quarter; the estimated trade size was $80.60 million based on quarterly average pricing. Meanwhile...
Apis Capital Trims Holdings of Celcuity Stock, According to Recent SEC Filing
On February 17, 2026, Apis Capital Advisors, LLC disclosed in an SEC filing that it sold 174,000 shares of Celcuity(NASDAQ:CELC), an estimated $14.30 million trade based on quarterly average prices. ...
Or get access to advanced financial data starting only $19.99
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.